Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer

Summary - Histological subtyping of non-small cell lung cancer (NSCLC) is of utmost importance for therapy stratification. Common immunohistochemical markers to identify squamous lineage are CK5/6, p40, and p63. Although p40 is considered the gold standard by current guidelines, the agreement of all...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Kriegsmann, Katharina (VerfasserIn) , Cremer, Martin (VerfasserIn) , Harms, Alexander (VerfasserIn) , Winter, Hauke (VerfasserIn) , Kazdal, Daniel (VerfasserIn) , Kriegsmann, Mark (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 21 February 2019
In: Pathology
Year: 2019, Jahrgang: 51, Heft: 3, Pages: 240-245
ISSN:1465-3931
DOI:10.1016/j.pathol.2018.11.009
Online-Zugang:Verlag, Volltext: https://doi.org/10.1016/j.pathol.2018.11.009
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0031302518304902
Volltext
Verfasserangaben:Katharina Kriegsmann, Martin Cremer, Christiane Zgorzelski, Alexander Harms, Thomas Muley, Hauke Winter, Daniel Kazdal, Arne Warth, Mark Kriegsmann

MARC

LEADER 00000caa a2200000 c 4500
001 1663669120
003 DE-627
005 20220816142219.0
007 cr uuu---uuuuu
008 190426s2019 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.pathol.2018.11.009  |2 doi 
035 |a (DE-627)1663669120 
035 |a (DE-599)KXP1663669120 
035 |a (OCoLC)1341210950 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Kriegsmann, Katharina  |d 1986-  |e VerfasserIn  |0 (DE-588)1049422449  |0 (DE-627)781924006  |0 (DE-576)40339774X  |4 aut 
245 1 0 |a Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer  |c Katharina Kriegsmann, Martin Cremer, Christiane Zgorzelski, Alexander Harms, Thomas Muley, Hauke Winter, Daniel Kazdal, Arne Warth, Mark Kriegsmann 
264 1 |c 21 February 2019 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 26.04.2019 
520 |a Summary - Histological subtyping of non-small cell lung cancer (NSCLC) is of utmost importance for therapy stratification. Common immunohistochemical markers to identify squamous lineage are CK5/6, p40, and p63. Although p40 is considered the gold standard by current guidelines, the agreement of all three markers is an important aspect for tumours more difficult to classify. A total of 1244 NSCLC including 569 squamous cell carcinomas (SqCC) and 675 adenocarcinomas were assembled on a tissue microarray and stained with CK5/6, p40, p63, TTF-1, and Napsin-A. Sensitivity and specificity for squamous lineage markers as well as agreement of CK5/6, p40 and p63 were calculated. Sensitivity of CK5/6, p40, and p63 for SqCC was 93%, 94%, and 94% and specificity was 98%, 97%, and 84%, respectively. Positivity for two of these markers was found in at least in 90% of SqCC. Highest agreement was observed for p40 and p63 (Cohen's kappa 0.80). We report a similar sensitivity of CK5/6, p40, and p63, but a decreased specificity of p63 as compared to CK5/6 and p40 for the identification of squamous lineage. Our results support the use of either CK5/6 or p40 over p63 in the routine diagnostic setting. 
650 4 |a CK5/6 
650 4 |a lung cancer 
650 4 |a NSCLC 
650 4 |a p40 
650 4 |a p63 
700 1 |a Cremer, Martin  |e VerfasserIn  |0 (DE-588)1084363852  |0 (DE-627)848800796  |0 (DE-576)456316078  |4 aut 
700 1 |a Harms, Alexander  |d 1988-  |e VerfasserIn  |0 (DE-588)1065129408  |0 (DE-627)815640749  |0 (DE-576)424796996  |4 aut 
700 1 |a Winter, Hauke  |e VerfasserIn  |0 (DE-588)1162076038  |0 (DE-627)1025509773  |0 (DE-576)176791531  |4 aut 
700 1 |a Kazdal, Daniel  |d 1983-  |e VerfasserIn  |0 (DE-588)114929650X  |0 (DE-627)1009614088  |0 (DE-576)496635867  |4 aut 
700 1 |a Kriegsmann, Mark  |d 1987-  |e VerfasserIn  |0 (DE-588)103740324X  |0 (DE-627)755668782  |0 (DE-576)39141870X  |4 aut 
773 0 8 |i Enthalten in  |t Pathology  |d Amsterdam : Elsevier, 1969  |g 51(2019), 3, Seite 240-245  |h Online-Ressource  |w (DE-627)271178310  |w (DE-600)1479244-8  |w (DE-576)079234585  |x 1465-3931  |7 nnas  |a Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer 
773 1 8 |g volume:51  |g year:2019  |g number:3  |g pages:240-245  |g extent:6  |a Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer 
856 4 0 |u https://doi.org/10.1016/j.pathol.2018.11.009  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0031302518304902  |x Verlag  |3 Volltext 
951 |a AR 
992 |a 20190426 
993 |a Article 
994 |a 2019 
998 |g 103740324X  |a Kriegsmann, Mark  |m 103740324X:Kriegsmann, Mark  |d 910000  |d 912000  |e 910000PK103740324X  |e 912000PK103740324X  |k 0/910000/  |k 1/910000/912000/  |p 9  |y j 
998 |g 114929650X  |a Kazdal, Daniel  |m 114929650X:Kazdal, Daniel  |d 910000  |d 912000  |e 910000PK114929650X  |e 912000PK114929650X  |k 0/910000/  |k 1/910000/912000/  |p 7 
998 |g 1162076038  |a Winter, Hauke  |m 1162076038:Winter, Hauke  |d 910000  |d 950000  |d 950900  |e 910000PW1162076038  |e 950000PW1162076038  |e 950900PW1162076038  |k 0/910000/  |k 1/910000/950000/  |k 2/910000/950000/950900/  |p 6 
998 |g 1065129408  |a Harms, Alexander  |m 1065129408:Harms, Alexander  |d 910000  |d 912000  |e 910000PH1065129408  |e 912000PH1065129408  |k 0/910000/  |k 1/910000/912000/  |p 4 
998 |g 1084363852  |a Cremer, Martin  |m 1084363852:Cremer, Martin  |d 910000  |d 910100  |e 910000PC1084363852  |e 910100PC1084363852  |k 0/910000/  |k 1/910000/910100/  |p 2 
998 |g 1049422449  |a Kriegsmann, Katharina  |m 1049422449:Kriegsmann, Katharina  |d 910000  |d 910100  |e 910000PK1049422449  |e 910100PK1049422449  |k 0/910000/  |k 1/910000/910100/  |p 1  |x j 
999 |a KXP-PPN1663669120  |e 3453535081 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1663669120","id":{"doi":["10.1016/j.pathol.2018.11.009"],"eki":["1663669120"]},"title":[{"title":"Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer","title_sort":"Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer"}],"note":["Gesehen am 26.04.2019"],"origin":[{"dateIssuedDisp":"21 February 2019","dateIssuedKey":"2019"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"person":[{"given":"Katharina","display":"Kriegsmann, Katharina","role":"aut","roleDisplay":"VerfasserIn","family":"Kriegsmann"},{"family":"Cremer","roleDisplay":"VerfasserIn","given":"Martin","role":"aut","display":"Cremer, Martin"},{"given":"Alexander","role":"aut","display":"Harms, Alexander","roleDisplay":"VerfasserIn","family":"Harms"},{"display":"Winter, Hauke","role":"aut","given":"Hauke","family":"Winter","roleDisplay":"VerfasserIn"},{"family":"Kazdal","roleDisplay":"VerfasserIn","given":"Daniel","display":"Kazdal, Daniel","role":"aut"},{"roleDisplay":"VerfasserIn","family":"Kriegsmann","given":"Mark","role":"aut","display":"Kriegsmann, Mark"}],"name":{"displayForm":["Katharina Kriegsmann, Martin Cremer, Christiane Zgorzelski, Alexander Harms, Thomas Muley, Hauke Winter, Daniel Kazdal, Arne Warth, Mark Kriegsmann"]},"physDesc":[{"extent":"6 S."}],"relHost":[{"recId":"271178310","pubHistory":["1.1969 -"],"id":{"eki":["271178310"],"zdb":["1479244-8"],"issn":["1465-3931"]},"title":[{"title":"Pathology","title_sort":"Pathology","subtitle":"the journal of the Royal College of Pathologists of Australasia"}],"note":["Gesehen am 09.11.2023"],"disp":"Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancerPathology","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Elsevier ; Taylor & Francis Group ; Informa Healthcare ; Wolters Kluwer Lippincott Williams & Wilkins","dateIssuedDisp":"1969-","dateIssuedKey":"1969","publisherPlace":"Amsterdam ; Abingdon ; London [u.a.] ; London [u.a.]"}],"part":{"pages":"240-245","year":"2019","extent":"6","volume":"51","issue":"3","text":"51(2019), 3, Seite 240-245"},"physDesc":[{"extent":"Online-Ressource"}]}]} 
SRT |a KRIEGSMANNAGREEMENTO2120